A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says
Eli Lilly has announced positive results for its experimental drug retatrutide, which targets three hormones related to weight loss. In a recent study, participants lost up to 28% of their body weight over 1.5 years, comparable to results from bariatric surgery. The company is conducting further studies to explore the drug's health benefits and compare it with other weight-loss medications.
- ▪Retatrutide helped participants lose up to 28% of their body weight over 1.5 years.
- ▪The drug targets three hormones, unlike current GLP-1 drugs that target one or two.
- ▪About 11% of participants on the highest dose stopped taking retatrutide due to side effects.
6 outlets in our directory ran this story, first to last over 8 hours. Coverage spans 3 points on the political spectrum — 1 lean left, 3 centre, 1 right.
- ▪ New obesity drug from Lilly delivers major weight loss — The Hill
- ▪ New Eli Lilly weight loss drug has dramatic effects in clinical trial — Washington Examiner
- ▪ Eli Lilly's next-generation weight loss injection posted record results in obesity trial — Quartz
- ▪ New Weight Loss Drug Retatrutide Delivers Stunning Results — TODAY.com
- ▪ Eli Lilly says next-generation weight loss drug clears crucial obesity trial — US Top News and Analysis
TIME — Top files mainly under news. We currently carry 213 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | TIME — Top |
| Canonical URL | https://time.com/article/2026/05/21/eli-lilly-new-weight-loss-drug/ |
| Publication time | Thu, 21 May 2026 16:01:21 +0000 |
| Retrieval time | 2026-05-21T16:11:31.008Z |
| Last seen | 2026-05-21T16:11:31.008Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | aBS1rBimYei- · 6 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Eli Lilly is reporting promising results for the first drug to target three hormones related to weight loss—not just one or two, as current GLP-1 drugs do. In a press release, the company reported that its experimental injectable drug, retatrutide, helped people who were overweight or obese to lose up to 28% of their body weight over 1.5 years compared to people receiving placebo. That’s on par with weight loss associated with bariatric surgery, says Kenneth Custer, executive vice president at Lilly and president of cardiometabolic health.The results add to previous findings on retatrutide among people with obesity and diabetes, which showed that the drug helped them lose 16.8% of their body weight compared to those taking placebo, in addition to lowering their blood sugar.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at TIME — Top.
Discussion
0 commentsMore from TIME — Top
